Here are relevant reports on : type-2-diabetes-market
-
US Digital Diabetes Management Market by Product (Device (CGM, Smart Glucometer, Insulin Patch Pump), Diabetes Apps, Service, Software & Platforms), Device Type (Handheld & Wearables), End User (Self/Home Healthcare) - Forecast to 2031
The US digital diabetes management market, valued at US$11.19 billion in 2025, stood at US$12.94 billion in 2026 and is projected to advance at a resilient CAGR of 11.9% from 2026 to 2031, culminating in a forecasted valuation of US$22.67 billion by the end of the period. The growth of the US digital diabetes management market is driven by the integration of AI-driven analytics, telehealth platforms, and interoperable ecosystems, which enhance clinical outcomes and patient engagement.
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
Digital Diabetes Management Market by Product (Device (CGM, Smart Glucometer, Insulin Patch Pump), Diabetes Apps, Service, Software & Platforms), Device Type (Handheld & Wearables), End User (Hospitals & Self/Home Healthcare) - Global Forecast to 2028
The global digital diabetes management market, valued at US$16.3 billion in 2022, stood at US$18.9 billion in 2023 and is projected to advance at a resilient CAGR of 13.6% from 2023 to 2028, culminating in a forecasted valuation of US$35.8 billion by the end of the period. The demand for better diabetes care solutions has grown of greater significance as diabetes prevalence has increased.
- Published: June 2023
- Price: $ 4950
- TOC Available:
-
Europe Digital Diabetes Management Market by Product (Device (CGM, Smart Glucometer, Insulin Patch Pump), Diabetes Apps, Service, Software & Platforms), Device Type (Handheld & Wearables), End User (Self/Home Healthcare) - Forecast to 2031
The Europe digital diabetes management market, valued at USD 6.89 billion in 2025, stood at USD 7.78 billion in 2026 and is projected to advance at a resilient CAGR of 10.0% from 2026 to 2031, culminating in a forecasted valuation of USD12.53 billion by the end of the period. Europe is a significant enabler of digital diabetes management. These devices generate continuous, real-time data that can be integrated into digital platforms for monitoring, alerts, and personalized insights.
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
Diabetes Market (Devices and Drugs)
Sedentary lifestyle has led to the increase in diabetic patients and increasing awareness of side effects caused if left undiagnosed has increased the number of patients turning out for diagnosis and regular check. Additionally diabetes devices has also been a leading market in home healthcare segment as well, with introduction of handy glucose monitors. The market is evidencing continued innovation addressing issues pertaining to painless and user friendly diagnostic devices, drugs with less side effects, Insulin delivery systems etc. The market dynamics in this industry compels the competitors to be aware of the competitive moves to enhance market revenues and retain market share
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
BRIC Diabetes Drugs Market (2010-2015) in Brazil, Russia, India, China
The prevalence of diabetes is increasing globally with the increase in life expectancy and rising incidence of obesity. Brazil’s diabetes drugs market is showing a double digit growth rate; while the Russian insulin market is also expected to witness significant growth with an estimated over 20 million patients in the region requiring diabetes treatment by 2025. India and China have the highest number of diabetics in the world – China alone is expected to have more than 71 million diabetic patients by 2025; and the similarly huge patient-base in India has already attracted a number of pharmaceutical companies such as Eli Lilly and Novo Nordisk. These companies are offering easy-to-use insulin versions to grab the market share in the Indian market for diabetes drugs. Thus, diabetes drugs market in BRIC economies is expected to have significant growth opportunities in the years to come.
- Published: April 2010
- Price: $ 4950
- TOC Available:
-
Diabetes Care Devices Market in Brazil, Russia, India, and China (BRIC) (2010 - 2014)
This market research report analyzes the diabetes care devices market in Brazil, Russia, India, and China (BRIC) over the period 2009-2014. The report categorizes the overall market for diabetes care devices into the submarkets for insulin pumps, self-monitoring blood glucose systems, and continuous glucose monitoring systems.
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
Active Pharmaceutical Ingredients (API) Market by type (Innovative, Generic), Synthesis (synthetic, biotech), Potency (HPAPI), Product (mAbs, hormones), Drug (OTC, Rx), Application (Diabetes, Oncology), Competitive landscape - Global forecast to 2030
The global active pharmaceutical ingredient market, valued at US$136.22 billion in 2024, stood at US$144.20 billion in 2025 and is projected to advance at a resilient CAGR of 6.6% from 2024 to 2030, culminating in a forecasted valuation of US$198.39 billion by the end of the period. The growth of the active pharmaceutical ingredients market is driven by the surge in demand for complex APIs, such as high-potency API, peptides, oligonucleotides, and increasing government incentives and supply chain reshoring.
- Published: October 2025
- Price: $ 4950
- TOC Available:
-
Biosimilars Market by Drug Class (mAbs (Adalimumab, Infliximab, Rituximab, Trastuzumab), GCSF, Insulin, Anticoagulant, rhGH, Teriparatide, GLP-1), Indication (Oncology, Autoimmune, Diabetes, Obesity), Competitive Landscape, Region - Global Forecast to 2035
The global biosimilars market, valued at US$32.75 billion in 2024, stood at US$35.04 billion in 2025 and is projected to advance at a resilient CAGR of 7.5% from 2025 to 2035, culminating in a forecasted valuation of US$72.29 billion by the end of the period. This growth is driven by several key factors, including a rising number of regulatory approvals and product launches, the patent expiries of major biologics, and the increasing prevalence of chronic diseases that require effective and affordable treatment options.
- Published: June 2025
- Price: $ 4950
- TOC Available:
-
Home Healthcare Market by Product (Therapeutic, Testing, Screening, Monitoring, Mobility Care), Service (Nursing, Infusion Therapy, Rehabilitation, Palliative Care), Indication (Cancer, Diabetes, CVD, Respiratory, Wound Care) - Global Forecast to 2030
The global home healthcare market, valued at US$285.3 billion in 2024, stood at US$309.9 billion in 2025 and is projected to advance at a resilient CAGR of 8.9% from 2025 to 2030, culminating in a forecasted valuation of US$473.8 billion by the end of the period. This growth is driven by the rising elderly population, which is more prone to chronic conditions such as hypertension, diabetes, and cardiovascular diseases, increasing the need for ongoing care at home.
- Published: August 2025
- Price: $ 4950
- TOC Available:
-
North America Injectable Drug Delivery Market – by Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] – Forecasts to 2017
The North American injectable drug delivery technologies market was valued at $9.3 billion in 2012; it is expected to reach $16.6 billion by 2017 at a CAGR of 12.3% from 2012 to 2017. Injectable drug delivery technologies are the combination of two major segments; devices and formulations. The North American injectable drug delivery formulations technologies market was the largest segment in this market. In addition, the market is segmented on the basis of its therapeutic applications. In therapeutic area, hormonal disorders command the major segment of injectable drug delivery technologies market due to high demand of injectable in treatment of diabetes. However, auto-immune diseases are the fastest growing segment of this market due to the advent of biologics (tumor necrosis factor (TNF) and Interleukin 1 (IL-1)) and improving patient compliance by the development of self injection devices.
- Published: April 2013
- Price: $ 4950
- TOC Available:
Records 1 to 10 of 50
